Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Retained Earnings (2018 - 2025)

10x Genomics' Retained Earnings history spans 8 years, with the latest figure at $225000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 145.64% year-over-year to $225000.0; the TTM value through Dec 2025 reached $225000.0, up 145.64%, while the annual FY2025 figure was $225000.0, 145.64% up from the prior year.
  • Retained Earnings for Q4 2025 was $225000.0 at 10x Genomics, up from -$1.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $225000.0 in Q4 2025 and bottomed at -$1.5 billion in Q3 2025.
  • The 5-year median for Retained Earnings is -$845.5 million (2021), against an average of -$662.5 million.
  • The largest annual shift saw Retained Earnings skyrocketed 473.08% in 2021 before it tumbled 4669909.38% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$863.3 million in 2021, then decreased by 19.23% to -$1.0 billion in 2022, then dropped by 24.78% to -$1.3 billion in 2023, then skyrocketed by 99.96% to -$493000.0 in 2024, then soared by 145.64% to $225000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXG's Retained Earnings are $225000.0 (Q4 2025), -$1.5 billion (Q3 2025), and $220000.0 (Q2 2025).